Jaguar Health explores strategic options, shares react ahead of Nasdaq investor forum
23.06.2026 - 16:09:31 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 16:07.
Jaguar Health, Inc. (US47010C1053) has started a formal review of strategic alternatives in tandem with its targeted New Drug Application for a crofelemer-based treatment in rare intestinal failure diseases, as disclosed in a June 22 press release. The Nasdaq-listed specialty pharmaceutical company links the review to maximizing stockholder value and its late-stage development plans for this program. Biospace report on Jaguar Health's strategic review
What Jaguar Health announced
According to the company, the board has engaged advisors and is examining a range of options, including potential transactions, partnerships, financings, or other strategic steps aligned with its planned NDA filing for the crofelemer-based candidate in intestinal failure disorders. Jaguar Health investor relations release of June 22, 2026 The strategic review is explicitly tied to the anticipated completion of clinical work supporting this filing.
Jaguar Health also highlighted that founder and CEO Lisa Conte will present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide an update on the crofelemer development program for rare intestinal failure diseases. Biospace report on Jaguar Health's strategic review The event gives Nasdaq investors and healthcare specialists a near-term opportunity to hear management detail the path toward the planned NDA.
How JAGX shares trade on Nasdaq
On Nasdaq, Jaguar Health shares recently closed at 2.59 US dollars, up 15.11 percent in the last session on June 22, 2026, according to TradingKey data. TradingKey technical overview for Jaguar Health The same source shows a market capitalization of around 2.03 million US dollars at that closing price.
Technical indicators paint a mixed picture: TradingKey reports Jaguar Health is trading between a resistance level at 3.47 US dollars and a support level at 1.93 US dollars, with its current price momentum score ranking it 157th out of 157 names in the pharmaceuticals industry. TradingKey technical overview for Jaguar Health Based on the site’s moving-average framework, the share currently shows more sell than buy signals.
All news and analysis on the Jaguar Health shares
Key releases on the strategic review, clinical milestones and Nasdaq trading data for Jaguar Health are bundled in the dedicated topic overview.
Analyst expectations and earnings picture
Consensus data compiled by TradingKey indicate that at least one analyst tracks Jaguar Health, with an average price target of 16.00 US dollars for the shares, identical to the high and low scenarios reported. TradingKey earnings and target overview for Jaguar Health This implies a target far above recent Nasdaq prices, although the data do not specify the time horizon.
The same source cites expected revenue of roughly 4.25 million US dollars and notes that Jaguar Health’s last reported quarterly loss per share of 4.38 US dollars compared with a market expectation of a 13.60 US dollar loss per share. TradingKey earnings and target overview for Jaguar Health For the next quarter, TradingKey lists a forecast loss per share of 1.49 US dollars.
The product and pipeline behind the stock
Jaguar Health’s core prescription asset is crofelemer, a gut-targeted chloride channel modulator originally commercialized for HIV-related noninfectious diarrhea, which the company is now developing in a crofelemer-based formulation for rare intestinal failure diseases, including short bowel syndrome and similar conditions. Jaguar Health investor presentation on the crofelemer program The strategic review the board initiated is explicitly aligned with the anticipated NDA for this rare-disease indication.
Where the JAGX shares trade today
The Jaguar Health shares (US47010C1053) most recently traded on Nasdaq at 2.59 US dollars as of 2026-06-22, 16:00 Eastern Time, based on TradingKey price data. TradingKey technical overview for Jaguar Health
Key data on the Jaguar Health shares
- Company: Jaguar Health, Inc.
- ISIN: US47010C1053
- WKN: A42ADK
- Ticker: JAGX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 2.59 USD
- Market cap: 2.03 million USD (as of 2026-06-22)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: not a member of major headline indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Historical figures and analyst estimates are subject to change. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
